DUEXIS Drug Patent Profile

Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

DrugPatentWatch^® Generic Entry Outlook for Duexis

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DUEXIS

International Patents:	25
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	154
Drug Prices:	Drug price information for DUEXIS
Drug Sales Revenues:	Drug sales revenues for DUEXIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DUEXIS
What excipients (inactive ingredients) are in DUEXIS?	DUEXIS excipients list
DailyMed Link:	DUEXIS at DailyMed

See drug prices for DUEXIS

See drug sales revenues for DUEXIS

Recent Clinical Trials for DUEXIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 4
Pediatric Rheumatology Collaborative Study Group	Phase 4

See all DUEXIS clinical trials

Paragraph IV (Patent) Challenges for DUEXIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUEXIS	Tablets	famotidine; ibuprofen	800 mg/26.6 mg	022519	1	2011-12-06

US Patents and Regulatory Information for DUEXIS

DUEXIS is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,067,451		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,309,127		Y
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,501,228
Horizon	DUEXIS	famotidine; ibuprofen	TABLET;ORAL	022519-001	Apr 23, 2011		DISCN	Yes	No	8,318,202		Y

International Patents for DUEXIS

When does loss-of-exclusivity occur for DUEXIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DUEXIS around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008011426
Portugal	2043637
European Patent Office	2043637	PROCÉDÉS ET MÉDICAMENTS DESTINÉS À L'ADMINISTRATION D'IBUPROFÈNE (METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN)
Japan	2009543885

Market Dynamics and Financial Trajectory for DUEXIS

Last updated: July 27, 2025

Introduction
DUEXIS, a combination medication comprising ibuprofen and famotidine, is designed to provide pain relief while mitigating gastrointestinal (GI) side effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs). It targets a specific segment within the broader anti-inflammatory and analgesic market, capturing demand from patients requiring NSAID therapy with reduced GI risk. Understanding its market dynamics and financial trajectory necessitates examining efficacy, competition, market adoption, regulatory landscape, pricing strategies, and broader healthcare trends.

Market Landscape and Demand Drivers
The global analgesic market is projected to reach over $23 billion by 2025, driven by rising chronic pain prevalence, aging populations, and expanding indications for NSAID use [1]. DUEXIS positions itself within this space by addressing unmet needs among patients prone to GI complications from NSAIDs. The conflict between the analgesic benefits of NSAIDs and their GI adverse effects fuels demand for combination therapies that offer a safer profile.

The primary demand driver for DUEXIS stems from clinicians seeking an alternative to traditional NSAIDs with added protective effects. According to prescribing data, GI adverse events account for substantial healthcare burdens, with ulcers and bleeding costing billions annually [2]. DUEXIS’s dual-action approach aims to reduce such complications, positioning it favorably in managed care settings and among high-risk patient groups such as the elderly.

Competitive Landscape
DUEXIS faces competition from several fronts, including traditional NSAIDs, proton pump inhibitors (PPIs), and other gastroprotective medications. Key competitors include prescriptions of ibuprofen alone, famotidine monotherapy, and emerging alternatives like acetaminophen, which is less effective for certain pain indications but lacks GI risks.

Branded alternatives such as Voltaren (diclofenac) and naproxen also compete within NSAID space. Additionally, newer drugs like celecoxib, a selective COX-2 inhibitor, offer comparable efficacy with potentially lower GI risk, although at a higher cost and with concerns about cardiovascular safety [3].

Regulatory and Reimbursement Environment
DUEXIS received FDA approval in 2010, with the drug’s success heavily reliant on payer coverage and formulary inclusion. Its adoption depends on the demonstration of cost-effectiveness relative to monotherapy NSAIDs or other GI-protective strategies. Reimbursement policies favor drugs that reduce hospitalizations and GI complications, positioning DUEXIS as a potentially cost-saving intervention for managed care organizations.

However, the pharmaceutical's trajectory was impacted by patent expirations and challenges in gaining widespread acceptance, partly due to concerns about polypharmacy and cost premiums associated with combination formulations.

Pricing Strategies and Revenue Potential
DUEXIS was initially priced higher than standard NSAIDs, justified by its GI safety profile. The market’s willingness to pay for this benefit depends on evidence of clinical benefits, cost savings from reduced GI events, and patient adherence.

Pricing pressures from payers and competitive generics have constrained revenue growth potential. As patent exclusivity waned, generic formulations of ibuprofen and famotidine further eroded market share. To sustain financial performance, the manufacturer explored indications expansion and combination with other therapies, though these efforts faced regulatory and commercial hurdles.

Market Adoption Trends and Future Outlook
In recent years, the adoption of DUEXIS has plateaued due to several factors: competition from lower-cost generics, skepticism about combination therapy’s added value, and a shift toward alternative pain management approaches (e.g., opioids, physical therapy). The emphasis on opioid-sparing strategies and the rise of non-pharmacological interventions have further challenged NSAID-centric therapies.

Emerging trends suggest that DUEXIS’s financial trajectory will remain constrained unless it can carve out a niche in specialized populations or leverage new indications. Enhanced focus on personalized medicine and biomarker-guided therapy could rejuvenate interest in tailored NSAID regimens with GI protection.

Pharmacoeconomic Considerations
Cost-effectiveness analyses indicate that DUEXIS’s added value hinges on its ability to prevent costly GI complications. Studies have demonstrated that in high-risk populations, GI protective agents can reduce hospitalization rates and improve quality-adjusted life years (QALYs). Yet, reimbursement and patient compliance remain critical barriers, especially when newer, cheaper alternatives are available.

Impact of Healthcare Policy and COVID-19
Healthcare policies promoting outpatient management and reducing hospital admissions favor drugs that prevent adverse events. The COVID-19 pandemic has increased focus on minimizing hospital stays, which could indirectly benefit drugs like DUEXIS when used prophylactically in at-risk patients.

Conversely, budget constraints and prioritization of novel therapeutics with higher clinical indicators may limit the financial upside for DUEXIS. This underscores the importance of demonstrating clear economic benefits in real-world evidence and health technology assessments.

Conclusion
The market dynamics for DUEXIS reflect a complex interplay of clinical need, competition, regulatory factors, and evolving healthcare priorities. While it possesses a unique positioning targeting GI safety in NSAID therapy, its financial trajectory faces headwinds from generic competition and shifting treatment paradigms. Strategic efforts to expand indications, optimize pricing, and demonstrate cost savings in high-risk populations are essential for improving its market potential.

---

Key Takeaways

• DUEXIS operates within a niche addressing GI safety in NSAID therapy, capitalizing on the high costs of GI complications.
• Competition from generics, alternative pain management drugs, and newer NSAID formulations constrains its growth prospects.
• Reimbursement strategies and cost-effectiveness evidence are critical for market adoption, especially among managed care organizations.
• Its future success depends on indication expansion, demonstrating economic value, and adaptation to healthcare trends favoring non-pharmacological pain management.
• Ongoing innovation and clinical data underpinning its safety and economic benefits will determine its long-term financial trajectory.

---

FAQs

1. What clinical advantages does DUEXIS offer over traditional NSAIDs?
DUEXIS combines ibuprofen with famotidine, providing effective pain relief while significantly reducing the risk of gastrointestinal ulcers and bleeding associated with NSAID use.

2. Why has DUEXIS struggled with widespread adoption?
Challenges include competition from generic NSAIDs and PPI options, concerns over added cost, limited awareness, and the shift toward alternative pain therapies.

3. How do reimbursement policies impact DUEXIS’s market performance?
Reimbursement decisions hinge on demonstrating cost-effectiveness, particularly in reducing GI complications; inadequate evidence can hinder formulary inclusion and prescribing.

4. What future strategies could enhance DUEXIS’s financial outlook?
Expanding onto new indications, reducing pricing, generating robust real-world evidence of economic benefits, and positioning as a therapy for high-risk populations are key strategies.

5. How does the landscape of pain management influence DUEXIS’s prospects?
The movement toward opioid-sparing approaches and non-invasive therapies may diminish demand for NSAID-based combination drugs like DUEXIS unless it can demonstrate distinct, superior benefits.

---

References
[1] MarketWatch. "Global Analgesics Market Size, Share & Trends," 2021.
[2] Crooks, C., et al. "Economic Burden of Gastrointestinal Bleeding," Journal of Hospital Medicine, 2020.
[3] FDA. "Celecoxib (Celebrex) Prescribing Information," 2019.